1. Home
  2. MIRM vs FOLD Comparison

MIRM vs FOLD Comparison

Compare MIRM & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • FOLD
  • Stock Information
  • Founded
  • MIRM 2018
  • FOLD 2002
  • Country
  • MIRM United States
  • FOLD United States
  • Employees
  • MIRM N/A
  • FOLD N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • FOLD Biotechnology: Pharmaceutical Preparations
  • Sector
  • MIRM Health Care
  • FOLD Health Care
  • Exchange
  • MIRM Nasdaq
  • FOLD Nasdaq
  • Market Cap
  • MIRM 2.5B
  • FOLD 2.9B
  • IPO Year
  • MIRM 2019
  • FOLD 2007
  • Fundamental
  • Price
  • MIRM $51.12
  • FOLD $6.13
  • Analyst Decision
  • MIRM Strong Buy
  • FOLD Strong Buy
  • Analyst Count
  • MIRM 9
  • FOLD 10
  • Target Price
  • MIRM $66.22
  • FOLD $26.89
  • AVG Volume (30 Days)
  • MIRM 351.2K
  • FOLD 3.8M
  • Earning Date
  • MIRM 08-11-2025
  • FOLD 07-31-2025
  • Dividend Yield
  • MIRM N/A
  • FOLD N/A
  • EPS Growth
  • MIRM N/A
  • FOLD N/A
  • EPS
  • MIRM N/A
  • FOLD N/A
  • Revenue
  • MIRM $379,251,000.00
  • FOLD $543,141,000.00
  • Revenue This Year
  • MIRM $36.76
  • FOLD $19.97
  • Revenue Next Year
  • MIRM $17.48
  • FOLD $22.92
  • P/E Ratio
  • MIRM N/A
  • FOLD N/A
  • Revenue Growth
  • MIRM 69.31
  • FOLD 28.25
  • 52 Week Low
  • MIRM $36.20
  • FOLD $5.51
  • 52 Week High
  • MIRM $54.78
  • FOLD $12.65
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 50.28
  • FOLD 50.50
  • Support Level
  • MIRM $50.92
  • FOLD $6.06
  • Resistance Level
  • MIRM $52.63
  • FOLD $6.77
  • Average True Range (ATR)
  • MIRM 1.49
  • FOLD 0.25
  • MACD
  • MIRM -0.35
  • FOLD 0.00
  • Stochastic Oscillator
  • MIRM 5.30
  • FOLD 28.09

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

Share on Social Networks: